Neuphoria Therapeutics (NEUP) Shares Outstanding (2022 - 2026)

Neuphoria Therapeutics (NEUP) has 5 years of Shares Outstanding data on file, last reported at $5.4 million in Q1 2026.

• Quarterly Shares Outstanding rose 190.04% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 190.04% YoY) and the FY2025 annual result came in at $2.0 million, up 79.22% from the prior year.
• Shares Outstanding steadied at $5.4 million in Q1 2026 per NEUP's latest filing, from $5.4 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $969.4 million in Q2 2022 and bottomed at $454465.1 in Q2 2023.
• The 5-year median for Shares Outstanding is $1.6 million (2024), against an average of $76.4 million.
• The widest annual swing landed in 2023, when Shares Outstanding slumped 99.95%; it then jumped 230.17% in 2025.
• Tracing NEUP's Shares Outstanding over 5 years: stood at $969.4 million in 2022, then tumbled by 99.91% to $891115.0 in 2023, then surged by 82.77% to $1.6 million in 2024, then jumped by 230.17% to $5.4 million in 2025, then changed by 0.0% to $5.4 million in 2026.
• Per Business Quant, the three latest NEUP Shares Outstanding figures stand at $5.4 million (Q1 2026), $5.4 million (Q4 2025), and $2.4 million (Q3 2025).

Peer Comparison